Basic Information



GTO ID GTC3990
Trial ID NCT00562003
Disease Ovarian Cancer | Peritoneum Cancer
Altered gene E1A|RGD
Therapeutic/Target gene Therapeutic gene
TherapyDNA oncolytic virus
Treatment Ad5-Delta 24RGD|DNX-2401|tasadenoturev
PhasePhase1
Recruitment statusCompleted
TitleA Phase I Study of a Tropism Modified Conditionally Replicative Adenovirus Vector (Ad5-Delta 24 RGD)for Intraperitoneal Delivery in Ovarian and Extraovarian Cancer Patients (Infectivity Enhanced Virotherapy for Ovarian Cancer)
Year2007
CountryUnited States
Company sponsorUniversity of Alabama at Birmingham
Other ID(s)F061005016 (UAB 0643)|UAB 0643
Vector information
Vectoradenovirus
ConstructAd5-Delta 24RGD
Vector typetumor-selective, replication-competent oncolytic adenovirus
Transgene/Inserted geneRGD-motif, which was engineered into the fiber H-loop, enabling the virus to use αvβ3 or αvβ5 integrins to enter cells.
Regulatory elementRGD-motif
Viral genome modification24-base-pair deletion in the E1A gene

Clinical Result

Cohort 1
Administration route intraperitoneal injection
Pts 26
Age Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph